3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Solid Tumors
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Advanced Solid Tumors
1
Interventions
Docetaxel
43
enzalutamide
31
Prednisone
25
Abiraterone Acetate
24
Magnetic Resonance Spectroscopy
18
abiraterone
15
pembrolizumab
14
bicalutamide
14
Radiotherapy
14
Cyclophosphamide
13
darolutamide
12
Leuprolide
12
Goserelin
12
apalutamide
10
Ipilimumab
10
olaparib
9
Specimen Handling
9
Radiosurgery
9
Radiation
9
Injections
9
Biopsy
9
Pluvicto
8
Paclitaxel
8
Radiotherapy, Intensity-Modulated
7
Carboplatin
7
sargramostim
6
fludarabine
6
cabazitaxel
6
Sirolimus
6
Nivolumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Prostatic Neoplasms
×
Dosage Forms
×
Clear all
NCT01784757
2021-03-17
ARAFOR
Orion Corporation, Orion Pharma
Phase 1
Completed
30 enrolled